A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be linked to longer progression-free survival in...
The latest OVATION-2 trial update, presented at the American Society of Clinical Oncology 2025 annual meeting, shows that adding intraperitoneal IMNN-001 to standard neoadjuvant chemotherapy improved both...